Inovio Shares To Benefit From Likelihood of Financing For COVID Vaccine, Benchmark Says

Inovio's SARS-CoV-2 vaccine candidate INO-4800 has a meaningful chance of progressing to Phase 2/3 in the July-August timeframe and securing the necessary financing from the government or nonprofits, Benchmark analyst Huseynov said in a note.

Noting that Inovio has a pipeline of vaccine candidates for various infectious diseases such as HIV, Ebola, MERS and Zika, the analyst said the company will get sufficient financial support for every promising vaccine candidate, including INO-4800.